Paper commissioned for the EFA Global Monitoring Report 2010, Reaching the marginalized
Senegal’s substantial and sustained progress against malaria is an inspiring public health success story, and a source of potential lessons for other countries on the path to elimination. This case study describes three major success factors—(1) outstanding leadership and partner engagement, (2)... the achievement and maintenance of high intervention coverage levels, and (3) a thriving data culture—and explores several exciting new opportunities to consolidate and expand upon Senegal’s two decades of impact.
more
Au cours des dix dernières années, les ONG humanitaires ont fait de plus en plus fréquemment appel aux Entreprises de sécurité privées (ESP). On observe l’existence d’un écart entre la manière dont les ONG utilisent les ESP dans la réalité et la régulation d’une telle relation. Ces ...orientations ont pour objet d’aider les ONG humanitaires à prendre une décision en connaissance de cause sur quand, comment et dans quelles conditions, recourir aux services d’une ESP. Ces orientations sont destinées aux responsables opérationnels des ONG au niveau du siège et du terrain. Ces orientations ne couvrent pas uniquement des activités de surveillance ou de protection armées, mais peuvent être appliquées à une gamme plus étendue de services assurés par les ESP.
more
Le gouvernement du Bénin a engagé le processus de mise en oeuvre du RAMU dans le but d’améliorer l’accessibilité fi nancière des populations à un paquet de base de soins de santé de qualité. Commencées en 2008, la réflexion, la préparation et la mise en oeuvre du RAMU au Bénin ont fa...it émerger des défi s et des questions divers au sein des acteurs impliqués dans le processus. Ces acteurs qui se retrouvent tant aux niveaux international, national et opérationnel, que dans les secteurs gouvernemental, non-gouvernemental et privé sont la cible principale de cette publication.
more
Review
Journal of Virus Eradication 2016 Jul; 2(3): 156–161.
Published online 2016 Jul 1.
PMCID: PMC4967967
PMID: 27482455
This report reviews and analyses the Affordable Medicines Programme, which was introduced in Ukraine in April 2017 to provide patients with improved access to 23 outpatient medicines for the treatment of chronic noncommunicable diseases. The evaluation combines both quantitative and qualitative anal...ysis. The findings confirm that the Programme has contributed to a significant increase in access to needed outpatient medicines in Ukraine. Further, while implementation was successful overall, uptake across regions was uneven. The report concludes by listing a number of policy options to support the sustainability and expansion of the Affordable Medicines Programme.
more
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep...ort is to provide forecasts of future demand for medicines used in the fields of HIV, viral hepatitis and STIs. This report jointly presents medicines forecasts across three disease areas in recognition of the benefits of addressing HIV, viral hepatitis and STIs in a coordinated manner.
more
Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.